Yes, there are two other development programs I didn't mention which utilise Novosorb BTM, but are the work of other entities founded by Prof. John Greenwood (and others).
The BetaCell Diabetes application, which you mentioned, is exploring the potential of NovoSorb BTM to host pancreatic islets in the skin. This program is being run by BetaCell Technologies with funding from the Juvenile Diabetes Research Foundation.
The Cultured Skin Composite application, which is being run by Skin TE, is seeding patient cells in NovoSorb foam substrate to grow bilayer skin suitable for grafting .
Pipeline, page-3
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
0.080(3.40%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $2.39 | $2.44 | $2.37 | $2.750M | 1.137M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1924 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.44 | 16040 | 4 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |